Back to Research Home
ABTAbbott Laboratories
Health Care · Health Care Equipment · Large
$103.70+1.16%
As of 23 Oct 2026Mkt cap $191B
Stage 13
WAIT
Fundamentals
48.8/75
Technical
9.5/15
Independent
58.2/90
GCAE viewelevated earnings event risk blocks an independent BUY decision
Price
- 1M
- +2.6%
- 3M
- −0.8%
- 6M
- +13.8%
- 1Y
- −19.0%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 33.3xHist median 21.5x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 10.9%
- Operating margin
- 16.3%
- FCF margin
- 16.7%
- Current ratio
- 1.6x
Growth
- Revenue growth
- +5.7%Latest FY YoY
- Revenue CAGR
- +0.7%
- EPS CAGR
- −1.4%
- FCF CAGR
- −3.8%
Capital
- Share-count trend
- −0.0%3Y annualised
- Net debt
- $5.6B0.6x OCF
Annual trend
- CAGR 2021–2025
- +0.7%
- Latest · 2025
- $44B
- YoY
- +5.7%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
elevated earnings event risk blocks an independent BUY decision
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2027-01-28
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded